Posted by Michael Wonder on 05 Jul 2025
Vitalgen's gene therapy drug VGN-R09b for primary Parkinson's disease receives FDA fast track designation
26 June 2025 - Shanghai Vitalgen announced that its gene therapy drug, VGN-R09b, for the treatment of primary Parkinson’s disease, has received fast track designation from the US FDA.
VGN-R09b received IND approvals in China and the US in 2024, as a first in class recombinant adeno-associated virus gene therapy that targets two key pathways for the treatment of Parkinson's disease.
